Please assess the completion status of the following clinical trial:

Trial Title: Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
KEY INCLUSION CRITERIA:~* Age 18 years or older~* All genders and ethnicity~* Positive HBsAg~* HBeAg positive and negative~* Pretreatment HBV DNA of 10,000 copies/mL or higher (for purposes of this study, both copies and equivalent IU measurements will be recorded and analyzed)~* Patients who are switched to, or prescribed, entecavir after treatment with adefovir for at least 12 weeks by the providing physician.~* Patients with and without prior lamivudine exposure will be enrolled but enrollment of lamivudine experienced cases will be limited to no more than 30 patients total~KEY EXCLUSION CRITERIA:~* Patients who refused to consent to the study~* Patients younger than 18~* Vulnerable subjects such as pregnant women, prisoners, employees, patients with significant cognitive deficits.~* Patients with prior exposure to another nucleoside for more than 2 weeks. Those with prior exposure to lamivudine will be enrolled under conditions detailed above.~* HIV co-infection~* HCV co-infection~* HDV co-infection~* Recipients of solid organ transplantation~* Patients who receive high-dose steroid (60 mg/d or higher and for longer than 10 days)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: None): Persistent viremia after 48 weeks or longer.
- Group 2 (Type: None): \<2 log IU/mL drop from initial HBVDNA after 12 weeks of adefovir
- Group 3 (Type: None): Patients who responded to adefovir and were switched to entecavir.
- Group 4 (Type: None): Patients with 160 copies/mL (100 IU/mL) or higher at the time of medication switch.

Based on this trial design, predict the completion outcome and termination type (if applicable).